Skip to content

Accelerate Your Drug Discovery

Accelerate Drug Discovery with High-Content, High-Throughput Imaging Solutions

A vast range of assays that we run on kidney, retina and lung models are visualised in our state-of-the-art imaging suite, which offers High-content imaging (HCI) capabilities, enhanced sensitivity and resolution to provide high-quality images and data that support accurate quantitative analyses.

Assays include:

 

With automated high-throughput screening (HTS) capabilities, and laser-based imaging system, the analysis process is accelerated, handling up to 1536-well plates with exceptional speed. You can leverage  automated workflows to improve accuracy and standardisation of experiments, obtaining consistent, high-quality outputs for your drug discovery and development needs.

For complex cell models and tissue analysis, the Zeiss Axio Observer with Apotome 3 system, offers high-resolution imaging with optical sectioning for fluorescence-based studies.

ImageXpress® Pico Automated Cell Imaging system from Molecular Devices enables high-throughput imaging for fast and efficient drug screening.

The ImageXpress® Confocal HT.ai High-Content Imaging system combines high-throughput, high-content, and high-sensitivity imaging in one platform. This platform’s heightened sensitivity makes it excellent for finding active target molecules, collecting bias-free data and expediting research with confident decision-making and strong data.

 

Speak to an Expert


Advantages of our comprehensive imaging suite

1.

High-throughput screening and multiplexing

2.

High-sensitivity for robust data

3.

More data for confident decision making

Related Reading

Imaging Capabilities

  • Zeiss Axio Observer with Apotome 3: High-resolution fluorescence imaging for complex cell models
  • ImageXpress® Pico: High-throughput automated imaging for faster drug screening
  • ImageXpress® Confocal HT.ai: High-content, high-sensitivity imaging for detailed phenotypic analysis

Services

  • High-throughput lung fibroblast-to-myofibroblast transition assay
  • Ciliary Beat Frequency Assay
  • Kidney transporter and toxicity assays

Specialised Assays

  • Retina toxicity and disease modelling
  • Automated, sensitive imaging for accurate drug compound analysis

Get our latest updates straight to your inbox

About Newcells Biotech

Newcells Biotech provides clients with validated in vitro tools to understand how drugs interact with tissues. We enable the generation of robust and informative data to support critical decisions during any stage of drug-development.

We believe that improving the in vitro models available to drug discovery and development scientists is a key method for increasing the efficiency of in-vitro to in-vivo translation and ultimately to delivering new therapies to patients.

By applying our expertise in iPSCs, primary tissues, a deep understanding of cellular physiology and organoid technology, we have built validated models and assays that have proven to be predictive of how drugs interact with tissues and organs.

Person working in lab

Retinal organoids at D180 of differentiation stained with Hoechst and Rhodopsin analysed with Axio Observer with Apotome 3 system (Zeiss) .
Fibroblast-to-myofibroblast (FMT) assay analysed with ImageXpress® Confocal HT.ai High-Content Imaging System (Molecular Devices) showing extracellular collagen deposition (pink), alpha smooth muscle actin (green) and cell nuclei (blue)

Contact us

Speak to one of our experts about your requirements.

Make an enquiry